Home LiteratureArticle Details
PMID: 2789930 Published · ppublish English Journal Article

Serum binding of nifedipine and verapamil in patients with ischaemic heart disease on monotherapy.

British journal of clinical pharmacology ·Vol. 28 ·No. 3 ·1989-09-00 ·Pages 357-61

Rumiantsev DO, Piotrovskii VK, Metelitsa VI, Slastnikova ID, Martsevich SYu, Kokurina EV

Abstract

Serum free fractions of nifedipine, verapamil and some of their metabolites were measured in patients with ischaemic heart disease receiving single oral dose and chronic monotherapy and were compared with those obtained in vitro. The percentages of unbound nifedipine and verapamil in vitro (concentration range 50-200 and 150-400 ng ml-1, respectively) were 2.51 and 7.23%, respectively, and did not differ from those found on monotherapy with these drugs (2.05 and 8.08%, respectively), and after single dosing. It is suggested that, during treatment with nifedipine or verapamil, their serum metabolites do not affect binding of the parent drugs to serum proteins.

MeSH Terms
Adult Blood Proteins/metabolism Coronary Disease/blood,drug therapy Dialysis Humans Male Middle Aged Nifedipine/blood,therapeutic use Protein Binding Verapamil/blood,therapeutic use
Chemicals
Blood Proteins Verapamil Nifedipine
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Rumiantsev D O
Institute of Noncommunicable Disease Prevention, USSR Research Centre for Preventive Medicine, Moscow.
Piotrovskii V K
Metelitsa V I
Slastnikova I D
Martsevich SYu
Kokurina E V
References (24)
24 references, click to expand
  1. Commentary: a physiological approach to hepatic drug clearance.
    Clin Pharmacol Ther. 1975 Oct;18(4):377-90 PMID: 1164821
  2. Physiological disposition of verapamil in man.
    Cardiovasc Res. 1976 Sep;10(5):605-12 PMID: 971476
  3. Factors affecting the plasma protein binding of verapamil and norverapamil in man.
    Res Commun Chem Pathol Pharmacol. 1980 Nov;30(2):329-39 PMID: 7444161
  4. Verapamil protein binding in patients and in normal subjects.
    Clin Pharmacol Ther. 1981 Jan;29(1):21-6 PMID: 6970111
  5. Verapamil disposition kinetics in chronic atrial fibrillation.
    Clin Pharmacol Ther. 1981 Jul;30(1):44-51 PMID: 7237897
  6. Direct determination of hepatic extraction of verapamil in cardiac patients.
    Clin Pharmacol Ther. 1981 Jul;30(1):52-6 PMID: 7237898
  7. Verapamil kinetics in normal subjects and patients with coronary artery spasm.
    Clin Pharmacol Ther. 1981 Nov;30(5):644-52 PMID: 7297023
  8. Reduced verapamil clearance during long-term oral administration.
    Clin Pharmacol Ther. 1981 Nov;30(5):701-6 PMID: 7297027
  9. Prediction of steady-state verapamil plasma concentrations in children and adults.
    Clin Pharmacol Ther. 1982 Aug;32(2):172-81 PMID: 7094504
  10. Prolongation of verapamil elimination kinetics during chronic oral administration.
    Am Heart J. 1982 Aug;104(2 Pt 1):198-203 PMID: 7102502
  11. Verapamil plasma binding: relationship to alpha 1-acid glycoprotein and drug efficacy.
    Clin Pharmacol Ther. 1983 Apr;33(4):485-90 PMID: 6831827
  12. Ion-exchange high-performance liquid chromatography in drug assay in biological fluids. II. Verapamil.
    J Chromatogr. 1983 Jun 10;275(1):195-200 PMID: 6874864
  13. Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration.
    Br J Clin Pharmacol. 1984 Apr;17(4):453-8 PMID: 6721991
  14. The first pass metabolism of nifedipine in man.
    Br J Clin Pharmacol. 1984 Dec;18(6):951-4 PMID: 6529535
  15. Nifedipine: influence of renal function on pharmacokinetic/hemodynamic relationship.
    Clin Pharmacol Ther. 1985 May;37(5):563-74 PMID: 3987180
  16. An investigation of the cause of accumulation of verapamil during regular dosing in patients.
    Br J Clin Pharmacol. 1985 Apr;19(4):512-6 PMID: 3994898
  17. Plasma levels and urinary excretion of verapamil, norverapamil, N-dealkylverapamil (D617), N-dealkylnorverapamil (D620) following oral administration of a slow-release preparation.
    Int J Clin Pharmacol Res. 1985;5(2):99-107 PMID: 4018947
  18. Disposition kinetics and urinary excretion of verapamil and some of its primary metabolites after oral administration in patients with angina pectoris.
    Int J Clin Pharmacol Ther Toxicol. 1986 Jan;24(1):4-11 PMID: 3957489
  19. Protein binding of nifedipine.
    J Pharm Pharmacol. 1986 May;38(5):399-400 PMID: 2872322
  20. Changes in antipyrine and indocyanine green kinetics during nifedipine, verapamil, and diltiazem therapy.
    Clin Pharmacol Ther. 1986 Aug;40(2):239-42 PMID: 3731687
  21. The effect of verapamil on antipyrine pharmacokinetics and metabolism in man.
    Br J Clin Pharmacol. 1986 Jun;21(6):655-9 PMID: 3741715
  22. The effect of oral verapamil therapy on antipyrine clearance.
    Br J Clin Pharmacol. 1986 Nov;22(5):606-9 PMID: 3790408
  23. The influence of binding to albumin and alpha 1-acid glycoprotein on the clearance of drugs by the liver.
    Pharm Weekbl Sci. 1987 Apr 24;9(2):65-74 PMID: 3295762
  24. Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs.
    Clin Pharmacokinet. 1987 Jun;12(6):402-32 PMID: 3301150
Article Info
Journal
British journal of clinical pharmacology
Abbr.
Br J Clin Pharmacol
ISSN
0306-5251
DOI
10.1111/j.1365-2125.1989.tb05438.x
Published
1989-09-00
Pages
357-61
Language
English
Region
England
NLM ID
7503323
PMCID
PMC1379956
Subset
IM
External Links
PubMed source DOI: 10.1111/j.1365-2125.1989.tb05438.x PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2